Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DB-1311 in combination with BNT327 or DB-1305 in advanced or metastatic solid tumors
CTR20252891Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of db-1311, pumitamig, DB-1305 in Nonhematologic neoplasms, sponsored by AbbVie Inc.. Started Oct 2025; status: active.
02
Drugs
db-1311pumitamigDB-1305
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252891.